Phentermine, sibutramine and affective disorders

Clinical Psychopharmacology and Neuroscience

Volumn 11, Issue 1, 2013, Pages 7-12

  An, Hoyoung ^a   Sohn, Hyunjoo ^b   Chung, Seockhoon ^c  

^a Jeju Environment Research Institute   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

^c University of Ulsan   (South Korea)

Author keywords

Affect; Anti obesity agents; Mood disorders; Obesity; Phentermine; Sibutramine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; DULOXETINE; EPHEDRINE; FENFLURAMINE; FLUOXETINE; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; PROLACTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; VENLAFAXINE;

ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DEPRESSION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DRUG POTENCY; DRUG WITHDRAWAL; DYSPHORIA; DYSPNEA; EUPHORIA; FLIGHT OF IDEAS; HAMILTON SCALE; HEART PALPITATION; HUMAN; HYPOMANIA; IRRITABILITY; LIFESTYLE MODIFICATION; LOW CALORY DIET; MANIA; MEDLINE; MOOD DISORDER; NONHUMAN; OBESITY; PROLACTIN BLOOD LEVEL; PSYCHOTIC MANIA; RESTLESSNESS; SIDE EFFECT; THOUGHT DISORDER; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84876937520     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2013.11.1.7     Document Type: Article

References (59)

1. Berkowitz RI, Fabricatore AN. Obesity, psychiatric status, and psychiatric medications. Psychiatr Clin North Am 2011;34:747-764.
2. de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010;178:230-235.
3. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002;63:528-533. (Pubitemid 34680363)
4. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003;64:1426-1435. (Pubitemid 41270100)
5. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich GS, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207-213. (Pubitemid 34407079)
6. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004;65:634-651.
7. Hirschfeld RM. Long-term side effects of SSRIs: sexual dysfunction and weight gain. J Clin Psychiatry 2003;64(Suppl 18):20-24.
8. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273-281. (Pubitemid 32423994)
9. Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET. Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther 2011;17:490-505.
10. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003;163:2058-2065. (Pubitemid 37151248)
11. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001;16:153-162. (Pubitemid 32402360)
12. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989;50:127-131. (Pubitemid 19117706)
13. Kaplan LM. Pharmacologic therapies for obesity. Gastroenterol Clin North Am 2010;39:69-79.
14. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39:32-41.
15. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005;65:1391-1418. (Pubitemid 41043893)
16. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-1095. (Pubitemid 41671605)
17. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;2011:179674.
18. John CE, Jones SR. Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology 2007;52:1596-1605. (Pubitemid 46843135)
19. Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. Eur J Pharmacol 2005;526:199-206. (Pubitemid 41744117)
20. Taber KH, Black DN, Porrino LJ, Hurley RA. Neuroanatomy of dopamine: reward and addiction. J Neuropsychiatry Clin Neurosci 2012;24:1-4.
21. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009;104:1085-1099.
22. Nakagawa T, Kaneko S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3, 4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N, N- diisopropyltryptamine (foxy). J Pharmacol Sci 2008;106:2-8. (Pubitemid 351159062)
23. Hendricks EJ, Greenway FL. A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther 2011;18:292-299.
24. Glatz AC, Ehrlich M, Bae RS, Clarke MJ, Quinlan PA, Brown EC, et al. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine. Pharmacol Biochem Behav 2002;71:197-204. (Pubitemid 34102479)
25. Alexander M, Rothman RB, Baumann MH, Endres CJ, Brasić JR, Wong DF. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 2005;56:94-99. (Pubitemid 40389560)
26. Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011;31(Suppl 1):5-17.
27. Teva Pharmaceuticals USA. Adipex-P drug label. 2012 [cited 2012 Jul. 1]. Available from http://www.adipex.com/contents/pdf/Adipex-pi.pdf.
28. Raison CL, Klein HM. Psychotic mania associated with fenfluramine and phentermine use. Am J Psychiatry 1997;154:711. (Pubitemid 27197611)
29. Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phentermine. J Clin Psychopharmacol 1996;16:189-190. (Pubitemid 26141757)
30. Cleare AJ. Phentermine, psychosis, and family history. J Clin Psychopharmacol 1996;16:470-471.
31. Zimmer JE, Gregory RJ. Bipolar depression associated with fenfluramine and phentermine. J Clin Psychiatry 1998;59:383-384. (Pubitemid 28373109)
32. Douglas A, Douglas JG, Robertson CE, Munro JF. Plasma phentermine levels, weight loss and side-effects. Int J Obes 1983;7:591-595. (Pubitemid 14239961)
33. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-342.
34. Food and Drug Administration. Qsymia (phentermine and topiramate extended-release) capsules approval letter 2012. 2012 [cited 2012 Jul. 1]. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory#apphist.
35. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A; OBD-202 Study Group. A randomized, doubleblind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007;30:1480-1486. (Pubitemid 46871158)
36. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000;1:127-139.
37. Halford JC, Wanninayake SC, Blundell JE. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998;61:159-168. (Pubitemid 28458908)
38. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 1999;126:1487-1495. (Pubitemid 29142081)
39. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine) 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm.
40. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880. (Pubitemid 34031892)
41. Naik S, Khoo CL, Lua R, Chai SB, Liew A, Sim K. Recurrent episodes of brief affective psychosis induced by sibutramine. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1359-1360.
42. Cordeiro Q, Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol 2002;5:283-284.
43. Benazzi F. Organic hypomania secondary to sibutraminecitalopram interaction. J Clin Psychiatry 2002;63:165. (Pubitemid 34173855)
44. Rocha FF, Bamberg TO, Pinto FC, Gomes LM, Silveira S. Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder. Rev Bras Psiquiatr 2008;30:400-401.
45. Elfhag K, Rössner S, Barkeling B, Rooth P. Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood. Pharmacol Res 2005;51:159-163. (Pubitemid 40040547)
46. Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. Nutr Metab Cardiovasc Dis 2008;18:207-210. (Pubitemid 351374797)
47. Abott Laboratories. Sibutramine drug label 2010. 2010 [cited 2012 Jul. 1]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 020632s034s035lbl.pdf.
48. Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring) 2007;15:2712-2722.
49. McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007;9:426-434. (Pubitemid 46865373)
50. Shakir SAW. Prescription-event monitoring. In: Strom BL, editor. Textbook of pharmacoepidemiology. 4th ed Chichester: John Wiley & Sons; 2005. p. 203-216.
51. Faulconbridge LF, Wadden TA, Berkowitz RI, Sarwer DB, Womble LG, Hesson LA, et al. Changes in symptoms of depression with weight loss: results of a randomized trial. Obesity (Silver Spring) 2009;17:1009-1016.
52. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 2012;63:132-146.
53. Astrup A, Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004;12(Suppl):167S-173S.
54. Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond) 2007;31:1140-1147. (Pubitemid 46987760)
55. Food and Drug Administration. Belviq (lorcaserin hydrochloride) approval letter 2012. 2012 [cited 2012 Jul. 1] Available from: http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label- ApprovalHistory#apphist.
56. Stahl SM. Stahl's essential psychopharmacology: The prescriber's guide. 4th ed. Cambridge: Cambridge University Press; 2011.
57. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-393. (Pubitemid 24337995)
58. Parikh SV, LeBlanc SR, Ovanessian MM. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Can J Psychiatry 2010;55:136-143.
59. Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, et al. A randomized, double-blind, placebocontrolled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res 2009;33:1863-1869.